ICLUSIG® expert videos

Valentín García-Gutiérrez

Servicio de Hematología
Hospital Universitario Ramón y Cajal (IRYCIS)
Madrid, Spain

Before the discovery of ICLUSIG, treatment failure in CML was devastating for patients^1–3

Valentín García-Gutiérrez Disclosures

Company/Organisation	Relationship(s)
Novartis, BMS, Incyte, Pfizer	Travel grants, research funding, advisory board

Simona Soverini

Institute of Hematology
‘L. & A. Seràgnoli’
University of Bologna
Bologna, Italy

ICLUSIG became the first and remains the only pan-inhibitor of BCR::ABL1 approved for CML in Europe, collectively suppressing all single point mutations (including T315I)^4–6

Simona Soverini Disclosures

Company/Organisation	Relationship(s)
Incyte	Consultancy

Jane Apperley

Centre for Haematology
Hammersmith Hospital
Imperial College London
London, UK

ICLUSIG has been with you since 2013, proudly demonstrating fast, deep and durable responses as seen in the long-term follow-up of the PACE study^6,7

Jane Apperley Disclosures

Company/Organisation	Relationship(s)
Incyte, Novartis, Paladin Labs	Speaker
Incyte, Novartis	Advisory boards
BMS, Incyte, Novartis, Pfizer	Research funding

Elias Jabbour

Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX, USA

We know that early use of ICLUSIG after one 2G TKI leads to the deepest responses^6,8

Elias Jabbour Disclosures

Company/Organisation	Relationship(s)
AbbVie, Amgen, Ascentage, ASTX, BMS, Novartis, Pfizer, Takeda	Research grants
AbbVie, Amgen, BMS, Genentech, Incyte, Novartis, Pfizer, Takeda	Consultancy and advisory roles

Gianantonio Rosti

IRCCS/SIRHHC Scientific Institute for Research, Hospitalization and Health Care ‘Dino Amadori’
Meldola (FC), Italy

The ELN 2020 recommendations named ICLUSIG as the preferred treatment in patients with resistance to a 2G TKI without mutations, unless cardiovascular risk factors preclude its use⁹

Gianantonio Rosti Disclosures

Company/Organisation	Relationship(s)
Novartis, Pfizer, Incyte	Consultant
Novartis, BMS, Pfizer, Incyte	Research support
Novartis, BMS, Pfizer, Incyte	Speaker bureau
Novartis, Incyte	Advisory board

Jorge Cortes

Georgia Cancer Center
Augusta, GA, USA

Thanks to the recent response-based dosing study, OPTIC, there's now clear evidence to induce response, reduce dose and maintain response with ICLUSIG to manage your patients^10,11

Induce response with 45 mg orally, once daily; reduce dose to 15 mg orally, once daily, upon achievement of ≤1% BCR::ABL1; maintain response with 15 mg orally, once daily.

Jorge Cortes Disclosures

Company/Organisation	Relationship(s)
BMS, Novartis, Pfizer, Takeda, Sun Pharma, Incyte	Consultant
BMS, Novartis, Pfizer, Takeda, Sun Pharma	Research support

ICLUSIG: Commitment to building patients’ futures

Since the initial approval of ICLUSIG in Europe in 2013, we have over 10 years of experience in treating patients with CML